BioLife SolutionsBLFS +0.89%72 Cyclically Adjusted PS Ratio is 15.31 as of Jul. 02, 2026, which is 9% above its 10-year median of 14.11. GuruFocus rates BLFS with a GF Score™ of 72/100 and a GF Value™ of $28.64 (Fairly Valued). The stock has 5 warning signs investors should review. Among 524 Medical Devices & Instruments companies, BioLife Solutions ranks worse than 93.7% on this metric.
The historical rank and industry rank for BioLife Solutions's Cyclically Adjusted PS Ratio or its related term are showing as below:
BLFS'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.16 Med: 14.11 Max: 44.47
Current: 15.29
During the past years, BioLife Solutions's highest Cyclically Adjusted PS Ratio was 44.47. The lowest was 2.16. And the median was 14.11.
BLFS's Cyclically Adjusted PS Ratio is ranked worse than 93.7% of 524
companies
in the Medical Devices & Instruments industry
Industry Median: 2.215
vs BLFS: 15.29
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
BioLife Solutions's adjusted revenue per share data for the three months ended in Mar. 2026 was $0.558. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.86 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
BioLife Solutions (NAS:BLFS) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
BioLife Solutions Cyclically Adjusted PS Ratio Related Terms
BioLife Solutions Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for BioLife Solutions's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioLife Solutions Cyclically Adjusted PS Ratio Chart
BLFS vs STAA, ATRC, KMTS: Cyclically Adjusted PS Ratio Comparison
For the Medical Instruments & Supplies subindustry, BioLife Solutions's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLife Solutions Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where BioLife Solutions's Cyclically Adjusted PS Ratio falls into.
BioLife Solutions Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
BioLife Solutions's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 15.31 mean?
BioLife Solutions (BLFS) has a Cyclically Adjusted PS Ratio of 15.31 as of Jul. 02, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioLife Solutions and its competitors. This is near median its historical median of 14.11. Over the past decade, BioLife Solutions' Cyclically Adjusted PS Ratio has ranged from 2.16 to 44.47. According to the industry distribution chart, BioLife Solutions ranks #491 out of 524 companies in the Medical Devices & Instruments industry, placing it in the top 93.7%.
Is BioLife Solutions' Cyclically Adjusted PS Ratio too high?
BioLife Solutions' current Cyclically Adjusted PS Ratio of 15.31 is near median its 10-year median of 14.11. Over the past 10 years, this metric has ranged from a low of 2.16 to a high of 44.47. The Medical Devices & Instruments industry median Cyclically Adjusted PS Ratio is 2.22. BioLife Solutions' value of 15.31 is 591.2% above this industry median. Based on the distribution chart, BioLife Solutions ranks #491 out of 524 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, BioLife Solutions has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' Cyclically Adjusted PS Ratio compare to STAA and ATRC?
According to the Medical Devices & Instruments industry distribution chart, BioLife Solutions ranks #491 out of 524 companies for Cyclically Adjusted PS Ratio. This places BioLife Solutions in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.22. BioLife Solutions' value of 15.31 is 591.2% above this benchmark. Historically, BioLife Solutions' own Cyclically Adjusted PS Ratio has ranged from 2.16 to 44.47 over the past decade. While the company's 10-year median is 14.11 vs. the industry median of 2.22, BioLife Solutions has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PS Ratio among Medical Devices & Instruments companies is 2.22, based on 524 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioLife Solutions's current Cyclically Adjusted PS Ratio of 15.31 is 591.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioLife Solutions and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PS Ratio is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLife Solutions's current Cyclically Adjusted PS Ratio is 15.31, which is near median its own 10-year median of 14.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (BLFS) is currently considered Fairly Valued. The stock's GF Value™ is $28.64, compared to a current price of $28.48 — trading 0.6% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 15.31, which is near median its 10-year median of 14.11 and 591.2% above the Medical Devices & Instruments industry median of 2.22. BioLife Solutions' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For BioLife Solutions (BLFS), the current Cyclically Adjusted PS Ratio is 15.31 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioLife Solutions (BLFS) Overvalued in 2026?
Based on GuruFocus' analysis, BioLife Solutions stock appears to be undervalued.
The current stock price of $28.48 is trading 0.6% below its estimated GF Value™ of $28.64.
GuruFocus considers BioLife Solutions to be Fairly Valued.
Key valuation signals for BLFS:
Cyclically Adjusted PS Ratio: 15.31 (near median its 10-year median of 14.11)
GF Value™: $28.64 vs. price of $28.48 (0.6% below fair value)
Industry Position: 591.2% above the Medical Devices & Instruments median (#491 of 524)
No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
72GF Score
Get the complete analysis for BLFS
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLFS has been successfully added to your 
